JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McBride, A. E.
Right arrow Articles by Silver, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McBride, A. E.
Right arrow Articles by Silver, P. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 5, 3128-3136, February 4, 2000


Analysis of the Yeast Arginine Methyltransferase Hmt1p/Rmt1p and Its in Vivo Function
COFACTOR BINDING AND SUBSTRATE INTERACTIONS*

Anne E. McBrideDagger §, Valerie H. WeissDagger , Heidi K. KimDagger , James M. HogleDagger , and Pamela A. SilverDagger §

From the Dagger  Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, and § Dana-Farber Cancer Institute, Boston, Massachusetts 02115

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Many eukaryotic RNA-binding proteins are modified by methylation of arginine residues. The yeast Saccharomyces cerevisiae contains one major arginine methyltransferase, Hmt1p/Rmt1p, which is not essential for normal cell growth. However, cells missing HMT1 and also bearing mutations in the mRNA-binding proteins Npl3p or Cbp80p can no longer survive, providing genetic backgrounds in which to study Hmt1p function. We now demonstrate that the catalytically active form of Hmt1p is required for its activity in vivo. Amino acid changes in the putative Hmt1p S-adenosyl-L-methionine-binding site were generated and shown to be unable to catalyze methylation of Npl3p in vitro and in vivo or to restore growth to strains that require HMT1. In addition these mutations affect nucleocytoplasmic transport of Npl3p. A cold-sensitive mutant of Hmt1p was generated and showed reduced methylation of Npl3p, but not of other substrates, at 14 °C. These results define new aspects of Hmt1 and reveal the importance of its activity in vivo.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Post-translational modifications are frequently used by cells to expand the repertoire of proteins to control their activity temporally or spatially or to target their degradation. The methylation of the guanidino group of arginine residues was first recognized 30 years ago (1), but recently more work has focused on this modification. Protein arginine methyltransferases have been identified and cloned from many eukaryotes (2-6). In addition, the number of potential substrates for these enzymes has grown as genome sequencing projects have revealed numerous proteins containing the RGG motif common to substrates for arginine methylation, many of which are RNA-binding proteins (7, 8). Although it is not yet clear what effect methylation may have on the activity of such proteins, the yeast arginine methyltransferase Hmt1p has been shown to facilitate the export of at least two of its substrates from the nucleus, pointing to the importance of methylation in nucleocytoplasmic transport (9).

Arginine methyltransferases were initially identified biochemically in mammalian cell lysates by their ability to transfer a radiolabeled methyl group from S-adenosyl-L-methionine (SAM)1 to histones, myelin basic protein, or the heterogeneous nuclear ribonucleoprotein A1 (10-14). In addition to monomethylated forms of these proteins, heterogeneous nuclear ribonucleoprotein A1 undergoes asymmetric dimethylation, resulting in NG,NG-methylarginine residues, whereas myelin basic protein is symmetrically methylated (NG,NG'-methylarginine) (3, 16, 11, 15). Sequence comparison of methyltransferases has revealed motifs common to enzymes that methylate different molecules (17); at least one of these motifs has been implicated in binding to their common co-factor, SAM (18). Novel proteins that contain these motifs have since been identified in general data base searches and in genetic screens (2-6, 19).

The first protein arginine methyltransferase gene in the yeast Saccharomyces cerevisiae, HMT1 (heterogeneous nuclear ribonucleoprotein methyltransferase), was identified in a screen for genes that interacted with NPL3, which encodes an RNA-binding protein (4). The same methyltransferase gene, alternately called RMT1, was also found in a systematic search of the yeast genome for proteins containing methyltransferase motifs (3). HMT1 is not an essential gene in yeast, but it is required in at least two separate genetic backgrounds: in strains with the temperature-sensitive npl3-1 allele or in strains lacking the 80-kDa cap-binding protein gene CBP80 (Delta cbp80) (4, 9). A search of ESTs for human homologs of HMT1 revealed two human methyltransferase cDNAs, HRMT1L1 and HRMT1L2, and HRMT1L2 was shown to substitute for HMT1 in npl3-1 strains (19). The ability of a human arginine methyltransferase to function in yeast indicates that cellular mechanisms involving protein methylation are conserved throughout eukaryotes.

The S. cerevisiae Hmt1 protein has been shown to have methyltransferase activity in vitro, methylating a range of RGG-containing proteins including yeast proteins Npl3p, Hrp1p and Hrb1p, and human heterogeneous nuclear ribonucleoprotein A1 (4, 9, 20). A major poly(A) RNA-binding protein in yeast, Npl3p, contains 15 RGG motifs and has been implicated in many cellular processes including nuclear transport, ribosome biogenesis, and silencing (21-25). Hrp1p has three RGG motifs and is a component of cleavage factor 1, which is required for mRNA cleavage and polyadenylation (26). In vitro methylation of recombinant Hrp1p had no effect on its specific binding to the polyadenylation efficiency element; however, binding of Hrp1p to RNA inhibits its methylation by Hmt1p (27). Npl3p has been shown to be methylated in vivo (4, 20), and there are at least three other proteins that are substrates for Hmt1p (3, 28).

Many known and potential substrates of arginine methyltransferases, including Npl3p, Hrp1p, and Hrb1p, are proteins that shuttle between the nucleus and the cytoplasm (9, 21, 26). The first evidence for the importance of HMT1 in cellular processes was the finding that it is required for efficient export of Npl3p and Hrp1p from the nucleus (9). The role of Hmt1p in protein export is also specific; Hrb1p export is not inhibited by the deletion of HMT1 (9).

Similar to Npl3p and Hrp1p, eukaryotic Cbp80p is involved in RNA processing and nuclear export of RNA-protein complexes (29-32). The lack of RGG tripeptides in Cbp80p, however, suggests that this protein is not likely to be a substrate for methylation. The lethality of Delta hmt1 Delta cbp80 strains may reflect the importance of methylation of Npl3p or other proteins involved in these processes in the absence of Cbp80p. Alternatively, Hmt1p may have cellular functions in addition to its role as a methyltransferase that are required in strains lacking CBP80.

We have now tested directly whether the methyltransferase activity is crucial for its biological function. In addition we have discovered a new mutation that affects the ability of Hmt1p to methylate certain substrates and have defined its effect in vivo.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Yeast Strains and Media-- The yeast strains used in this study are listed in Table I. All strains were grown and genetic manipulations performed as described previously (33). The plasmids used here are listed in Table II. Oligonucleotides used in plasmid construction and sequencing were synthesized at Integrated DNA Technologies, Inc. and are shown in Table III. All sequences that were amplified by PCR were verified by automatic sequencing at the Dana-Farber Cancer Institute Molecular Biology Core Facility.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Yeast strains used in this study

                              
View this table:
[in this window]
[in a new window]
 
Table II
Plasmids used in this study

                              
View this table:
[in this window]
[in a new window]
 
Table III
Oligonucleotides used in this study

Construction of G68 Mutant hmt1 Alleles-- HMT1 sequences were amplified by PCR from pPS1307 with oligonucleotides 5'HMT1a and either AM2 or AM3 to introduce mutations that would result in 1) an Arg or Ala change at amino acid 68, respectively, and 2) the loss of a KpnI site. The PCR products were digested with AgeI and NcoI, and pPS1307 was partially digested with NcoI, then digested with AgeI. The 7-kilobase pair fragment of pPS1307 was ligated to each 526-base pair PCR product, resulting in plasmids pPS1750 (G68R) and pPS1751 (G68A). The 2.7-kilobase pair XbaI fragments from pPS1750 and pPS1751 were ligated into the SpeI site of either pRS315 or pRS305, resulting in plasmids pPS1752 and pPS1753 or pPS1760 and pPS1761, respectively. The integration plasmids pPS1760 and pPS1761 were linearized with NcoI, transformed into PSY865 (Delta hmt1::HIS3) or PSY1812 (Delta hmt1::HIS3 npl3-27),2 and selected on plates lacking leucine. Integrated alleles were confirmed by Southern blot analysis or PCR, and expression and activity of mutant Hmt1 proteins were tested by immunoblotting.

Bacterial Expression of His-Hmt1 Proteins-- His-Hmt1p expression plasmids were constructed as follows. HMT1 sequences were amplified by PCR from plasmids pPS1750 (G68R), pPS1751 (G68A), and pPS1759 (E18V) using primers HMT5'NDE and HMT3'BAM. Resulting fragments were digested with NdeI and BamHI and ligated into the NdeI and BamHI sites of pET-15b. Amplified sequences were verified by automatic sequencing. Purification of recombinant His-Hmt1 proteins, His-Hrp1p, and Npl3-myc was as described in Shen et al. (9). A polyclonal rabbit antiserum was raised against purified His-Hmt1p at Covance Research Products, Inc.

Immunoblot Analysis-- Strains were grown overnight in the appropriate medium and then diluted and grown at the appropriate temperature. The cells were at mid-log phase (about 107 cells/ml) when harvested. For expression studies, yeast cell pellets were frozen before lysis in radioimmune precipitation buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8.0) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride and 2.5 µg/ml each leupeptin, chymostatin, antipain, pepstatin A, and aprotinin) using a Fast-Prep instrument (Bio 101) set at 6.5 for 30 s. Insoluble material was pelleted by centrifugation at 4 °C for 10 min, and the protein concentration of the supernatant was determined by Bio-Rad assay. Indicated amounts of total protein were resolved by SDS, 10% PAGE (34) and immunoblotted essentially as described previously (35). Blots were incubated overnight in phosphate-buffered saline with 0.25% Tween (PBST), 2.5% milk powder and different dilutions of primary antibody (anti-Hmt1p serum, 1:5000; anti-Npl3p serum, 1:1000 (24); 1E4 antibody 1:500, provided by M. Swanson (Gainesville, FL) (36)). After washing in PBST, blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody solution (1:5000 in PBST with milk; Jackson Immunoresearch Laboratories) and washed, and proteins were detected by enhanced chemiluminescence (Amersham Pharmacia Biotech).

In Vitro Methyltransferase Activity Assays-- Methyltransferase activity assays were performed in a 15-µl reaction containing 20 mM MOPS, pH 7.2, 400 mM KCl, 2 mM EDTA, 30 µM SAM (Sigma), 3.5 µCi of [methyl- 3H]SAM (NEN Life Science Products, 80 Ci/mmol) in addition to enzyme and substrate proteins. In the case of the G68 mutants, 2 µg of enzyme and 2 µg of substrate were used to test methylation of His-Hrp1p. To test the methylation of Npl3-myc by the G68 mutants, 0.2 µg each of enzyme and substrate were used. The reactions were incubated at 30 °C for 30 min.

For the methylation of His-Hrp1p and Npl3p-myc by wild-type Hmt1p and the E18V mutant Hmt1p, reactions were performed in the reaction mix described above, but with 0.7 µM substrate and with increasing amounts of enzyme ranging from 0.07 µM to 7.0 µM. Methylation of the peptide FGGRGGF, which was synthesized by Charles E. Dahl (Biopolymers Facility, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School), was carried out similarly, but with lower enzyme:substrate ratios. The final concentration for the peptide was 100 µM, with enzyme concentrations ranging from 0.1 µM to 10 µM. Reactions were incubated at 14 °C or 30 °C for 30 min. All reactions were terminated by the addition of SDS-PAGE sample buffer and boiling. Samples were resolved by SDS-10% PAGE (15% for peptide) followed by Coomassie staining and fluorography (Entensify; NEN Life Science Products). Autoradiographs were exposed for 4-16 h at -80 °C.

Immunofluorescence Microscopy-- Localization of Npl3p by immunofluorescence microscopy was performed essentially as described previously (37). Wild-type and npl3-27 strains were grown to mid-log phase at 25 °C and then shifted to 37 °C for 30 min. Cells were fixed in formaldehyde for 1 h at 37 °C before preparation for microscopy. A 1:1000 dilution of anti-Npl3p and a 1:100 dilution of Texas red-conjugated anti-rabbit antibody were used to detect Npl3p.

Generation of Conditional hmt1 Alleles-- HMT1 sequences were amplified from pPS1307 by PCR using a variety of conditions to optimize the degree of mutagenesis. All 100-µl reactions contained 1 µl of Taq polymerase (Amplitaq, Perkin-Elmer), 20 nmol of pPS1307, 50 pmol each of primer 5'HMT1a and 3'HMT1a, 7 mM MgCl2, 1× Perkin-Elmer PCR buffer. Mutagenesis was increased by using 1 mM dTTP, 1 mM dCTP, 0.2 mM dATP, and 0.2 mM dGTP rather than 0.5 mM each dNTP or by also adding 0.5 mM MnCl2 (38).

PCR fragments were purified by elution from Qiaquick columns (Qiagen) and co-transformed into PSY1191 with pPS1305 that had been digested with NcoI and MscI. Strains that contained gap-repaired plasmids were selected at 25 °C on plates lacking leucine and then transferred to 5-FOA plates lacking leucine to select for strains that had lost pPS1307. Candidate conditional alleles were identified by transferring cells to YEPD plates at 13 °C, 25 °C, and 37 °C and selecting strains that grew at 25 °C but not at one of the two possible restrictive temperatures. Plasmids were rescued from these strains and retransformed into PSY1191 to test plasmid linkage of the conditional phenotype.

Amplification of HMT1 with Taq polymerase in the absence of further mutagenic conditions resulted in 2-7% lethality. After screening of 26,500 colonies from these transformations, no candidates were identified. Screening of 18,000 colonies from PCR reactions containing altered dNTP concentrations (11-17% lethality) also resulted in no candidate conditional alleles. However, when PCR conditions were altered by changing dNTP concentrations and adding manganese chloride (60% lethality), cold-sensitive alleles were found after screening 20,000 colonies. The hmt1 alleles that caused conditional growth after retransformation were sequenced from plasmids pPS1757 (hmt1-20) and pPS1758 (hmt1-46) with oligonucleotides 5'HMT1a, AM4, AM7, and AM8.

To separate N-terminal and C-terminal mutations in the conditional hmt1 alleles, 0.5-kilobase pair NcoI-AatII fragments were exchanged between plasmid pPS1305 and plasmids pPS1757 and pPS1758. Two mutations, one leading to an E18V substitution and the other introducing a silent HindIII site 5' to the E18 codon, were introduced into pPS1305 by QuikChange mutagenesis (Stratagene) using gel-purified oligonucleotides AM9 and AM10, following the manufacturer's protocol. The resulting plasmid, which contained the hmt1-E18V allele, was pPS1759.

Plasmids for integration of hmt1-20, hmt1-46, and hmt1-E18V alleles were constructed by ligating the 3.5-kb BamHI-HpaI fragment from plasmids pPS1757, pPS1758, and pPS1759 into pRS305 that had been digested with BamHI and HpaI. Integration was performed, and integrated alleles were confirmed as for G68 mutant alleles. Synthetic lethality of integrated alleles was tested by mating with PSY1191 (Delta hmt1 Delta cbp80) or PSY773 (npl3-1) and subsequent tetrad analysis.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Mutations in the SAM Binding Motif Disrupt Activity of Hmt1p-- To test the importance of methyltransferase activity of Hmt1p in vivo, we wished to design point mutations in Hmt1p that would disrupt its catalytic activity (Fig. 1). Sequence alignments of methyltransferases have revealed sequence motifs shared by a diverse set of proteins (17), and the location of these motifs in Hmt1p is shown schematically (Fig. 1A). Although residues involved in substrate binding vary among methyltransferases that target nucleic acids, proteins, and small molecules, motifs I and post-I (Fig. 1B) are involved in binding to the cofactor SAM (3, 18, 39, 40).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Methyltransferase motifs in Hmt1p. A, the primary structure of Hmt1p is shown schematically. The methyltransferase motifs are shaded. B, alignment of motifs I and post-I from various methyltransferases: Hmt1p (GenBankTM accession number S45890), the most closely related human arginine methyltransferase (HRMT1L2; accession number Y10807), Escherichia coli ribosomal protein L11 methyltransferase (prmA; accession number S67010), and E. coli DNA methyltransferase EcoP15I (accession number X06287). The highly conserved penultimate glycine of motif I is shown in boldface, and the post-I motif glycine mutated in the hmt1-1 allele is marked with an asterisk. Note that resequencing of the HRMT1L2 cDNA revealed that the last residue in the post-I motif was a glutamate rather than a valine. H. sapiens, Homo sapiens.

A mutation in the EcoP15I DNA methyltransferase, changing the highly conserved penultimate glycine in motif I (bold, Fig. 1) to a serine or an arginine, reduced the in vitro methyltransferase activity more than 400-fold (41). We therefore chose to mutate the equivalent residue in Hmt1p, G68. This residue was mutated to either an arginine or an alanine, as a more conservative change, and the mutant proteins were tested for methyltransferase activity and biological function.

To determine expression levels of wild-type and mutant Hmt1 proteins, an antiserum was raised in rabbits immunized with recombinant, histidine-tagged Hmt1p. Fig. 2A demonstrates that the antiserum recognizes both the original antigen (lanes 1-4), which migrates as a 45-kDa protein, and endogenous yeast Hmt1p (lanes 5 and 6), which migrates as a 40-kDa protein. The absence of a band in lysate from cells lacking HMT1 (Delta hmt1) and the lack of other molecular weight bands indicates the high specificity of the antiserum. Comparison of the His-Hmt1p and wild-type lysate dilution series allowed an approximate calculation of the amount of Hmt1p in the cell, which was ~4 × 105 molecules/cell.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   A, anti-Hmt1p serum recognizes only Hmt1p. A polyclonal serum was raised in rabbits against recombinant, histidine-tagged Hmt1p. The original antigen and yeast lysates were resolved by SDS-PAGE, and immunoblot analysis was used to assess the specificity of the antiserum. Lanes 1-4 contain a dilution series of His-Hmt1p (40, 8, 1.6, 0.32 ng). Lanes 5 and 6 contain wild-type yeast lysate (10 and 1 µg total protein; PSY867), and lane 7 contains 10 µg of total lysate from Delta hmt1 cells (PSY865). B, in vivo methylation of Npl3p by wild-type and mutant Hmt1 proteins. Mutant hmt1 alleles with G68 changed to either an alanine (A) or an arginine (R) were integrated into a Delta hmt1 strain (PSY865) such that only the mutant Hmt1p was expressed. Cells were grown at 25 °C to mid-log phase and lysed, and total protein was resolved on SDS-PAGE gels. Samples were analyzed by immunoblotting with anti-Hmt1p and anti-Npl3p antisera and the monoclonal antibody 1E4, which specifically recognizes methylated Npl3p. All immunoblots compare protein levels in the mutant strains with those in the Delta hmt1 strain and in a wild-type (HMT1) strain (5-fold dilution series). Lanes 1, 2, 5, 6 contain 5 µg of total protein, lane 3 contains 1 µg, and lane 4 contains 0.2 µg of total protein for anti-Hmt1p and anti-methyl Npl3p. Half as much total lysate was used for the anti-Npl3p blot.

To test the in vivo expression and activity of mutant Hmt1 proteins, mutated alleles were integrated into the genome of Delta hmt1 cells such that only mutant forms were expressed. Both mutant alleles expressed Hmt1p to the same level as the wild-type strain (top panel, Fig. 2B). In addition, the anti-Npl3p immunoblot shows that equivalent amounts of Npl3p were found in the lysates (middle panel, Fig. 2B).

Swanson and co-workers (36) raised a monoclonal antibody, 1E4, against purified yeast Npl3p. The ability of this antibody to recognize Npl3p in yeast lysates but not recombinant bacterially expressed Npl3p led to a series of experiments showing that this antibody specifically recognizes methylated Npl3p, although its exact epitope has not been elucidated (20). We used 1E4 to determine the activity of the mutant Hmt1 proteins in vivo. The 1E4 immunoblot (bottom panel, Fig. 2B) reveals that the methylation of Npl3p in strains expressing mutant Hmt1 proteins is significantly reduced compared with that in the wild-type strain at 25 °C. As expected, Hmt1-G68A, with its less disruptive amino acid change, retains some activity (down >5- but <25-fold), whereas Hmt1p with arginine at position 68 has no detectable activity (>25-fold less than wild type).

The loss of in vitro methyltransferase activity of recombinant G68 mutant Hmt1 proteins correlates with their reduced in vivo activities (Fig. 3). Histidine-tagged wild-type and mutant Hmt1 proteins were expressed in bacteria, purified, and tested for methylation activity. Equal amounts of His-Hmt1p and substrate were incubated with [methyl-3H]SAM to test if mutant proteins were able to methylate either His-Hrp1p or Npl3-myc. Hmt1-G68A (lanes 2 and 5) was less active than wild-type Hmt1p (lanes 1 and 4) when either His-Hrp1p or Npl3-myc was used as a substrate (Fig. 3). Hmt1-G68R, however, failed to methylate either substrate (lanes 3 and 6).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Hmt1p G68 mutants have decreased methylation activity in vitro. Recombinant wild-type (WT), G68A, and G68R mutant proteins were analyzed for their abilities to methylate both the Hrp1p and Npl3p substrate proteins. Lanes 1-3 show wild-type, G68A, and G68R, respectively, methylating His-Hrp1p (2 µg each enzyme and substrate), and lanes 4-6 show them methylating Npl3p-myc (0.2 µg each of enzyme and substrate). Methylation reactions containing 30 µM SAM and 3.5 µCi of [methyl-3H]SAM were incubated for 30 min at 30 °C before SDS-PAGE.

SAM-binding Site Mutations Disrupt Hmt1p Function in Vivo-- To study the in vivo effect of these mutations that inhibit methyltransferase activity, we took advantage of strain backgrounds that require HMT1. Plasmids that express the mutant proteins were transformed into Delta hmt1 npl3-1 and Delta hmt1 Delta cbp80 strains bearing an HMT1 URA3 plasmid to test for their ability to suppress the synthetic lethality. The growth of strains that had lost the URA3 plasmid bearing the wild-type HMT1 was monitored on FOA plates at 25 °C (Fig. 4). Neither mutant hmt1 was able to suppress the Delta hmt1 npl3-1 synthetic lethality after 3 days of growth (Fig. 4A), and hmt1-G68A only partially suppressed the Delta hmt1 Delta cbp80 synthetic lethality after 4 days of growth (Fig. 4B). Thus, methyltransferase activity correlates with growth in the Delta cbp80 background, whereas complete wild-type methyltransferase activity appears to be necessary in the npl3-1 background. Therefore, the methyltransferase activity of Hmt1p is important for its function in vivo.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Mutations in G68 are synthetically lethal with npl3-1 and Delta cbp80. Synthetic lethal strains Delta hmt1 npl3-1 (PSY866; A) and Delta hmt1 Delta cbp80 (PSY1191; B) bearing a URA3 HMT1 CEN plasmid were transformed with LEU2 CEN plasmids that express either no Hmt1p (vector), wild-type (WT) Hmt1p, or mutant Hmt1 proteins (G68A or G68R). Cells were transferred to 5-FOA plates and tested for their ability to grow at 25 °C (3-4 days).

To test whether methyltransferase activity of Hmt1p is important for Npl3p export from the nucleus, we used the npl3-27 allele, which encodes a mutant Npl3 protein that is imported slowly into the nucleus (37). In the presence of HMT1, wild-type Npl3p is predominantly nuclear at 37 °C, whereas npl3-27p is found throughout the cell (Fig. 5 (21)). In the presence of G68 mutant hmt1 alleles, however, the steady state localization of npl3-27p becomes more nuclear. The severity of this phenotype correlates with loss of methyltransferase activity. Nuclear npl3-27p is found in <50% of hmt1-G68A cells, whereas npl3-27p is concentrated in the nucleus of 60-80% of hmt1-G68R cells. Thus methyltransferase activity of Hmt1p facilitates export of Npl3p.


View larger version (106K):
[in this window]
[in a new window]
 
Fig. 5.   Methyltransferase activity of Hmt1p affects localization of Npl3p. Yeast strains PSY867 (wild type (WT)), 1031 (npl3-27), 1826 (npl3-27, G68A), and 1825 (npl3-27, G68R) were grown to mid-log phase at 25 °C and then shifted to 37 °C for 30 min. After a 1-h fixation in formaldehyde at 37 °C, cells were prepared for immunofluorescence microscopy. Npl3p was detected with the anti-Npl3p polyclonal antiserum and a Texas red-conjugated anti-rabbit antibody. Nuclei were visualized by staining with 4,6-diamidino-2-phenylindole (DAPI).

Generation of Cold-sensitive Alleles of Hmt1p-- To investigate further the in vivo function of HMT1, we again took advantage of its being essential in Delta cbp80 strains to generate conditional alleles of hmt1. Error-prone PCR was used to amplify and to introduce random mutations into HMT1 sequences. The entire HMT1-coding region and some 5'- and 3'-noncoding sequences were excised from a LEU2 HMT1 CEN plasmid. The gapped plasmid and PCR product were co-transformed into a Delta hmt1 Delta cpb80 strain that contained a URA3 HMT1 CEN plasmid (PSY1191). After in vivo gap repair (42), the URA3 plasmid was eliminated by transferring Leu+ colonies to FOA. LEU2 plasmids bearing temperature-sensitive or cold-sensitive mutant hmt1 alleles were then identified by plating on rich medium at different temperatures.

Two plasmids, pPS1762 and 1763, still showed conditional suppression of synthetic lethality when retransformed into the Delta hmt1 Delta cpb80 strain. The hmt1 alleles in these plasmids were named hmt1-20 and hmt1-46. Delta hmt1 Delta cpb80 strains bearing these alleles can grow on FOA plates at 25 °C but not at 14 °C, demonstrating the cold sensitivity of these alleles (compare hmt1, upper left section and wild-type HMT1, top section, Fig. 6A).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Cold-sensitive hmt1 alleles generated in Delta hmt1 Delta cbp80 background. A, PCR mutagenesis of HMT1 and screening of mutant alleles in PSY1191 (Delta hmt1 Delta cbp80 + HMT1 URA3 CEN) revealed two cold-sensitive alleles of hmt1. PSY1191 was transformed with LEU CEN plasmids bearing wild-type HMT1, the original mutant alleles (hmt1-20 and hmt1-46; hmt1), separated N-terminal and C-terminal mutations (N-ter. and C-ter.), or the single point mutant allele hmt1-E18V. Transformants were transferred to FOA plates lacking leucine and grown at 14 °C (3 weeks) or 25 °C (3-4 days). B, the location of mutations in the hmt1 alleles and the division between N-terminal and C-terminal mutations used in A are shown. Restriction sites and oligonucleotides (arrows) used in mutagenesis are also shown. Note that both original alleles contain one mutation in common, the E18V mutation.

Given that the conditions used for mutagenesis were predicted to result in multiple mutations, the N- and C-terminal mutations were subcloned separately into the wild-type HMT1 plasmid pPS1305. The cold sensitivity of each allele mapped to the N terminus (Fig. 6A, compare lower left and bottom sections). Sequencing of the 5'-noncoding region, the open reading frame and a portion of the 3'-noncoding region revealed that each allele did contain multiple mutations (Fig. 6B). Remarkably, the two alleles shared one mutation in common, A to T at nucleotide 53 of the open reading frame. This mutation resulted in the substitution of a valine for glutamate 18 of Hmt1p (E18V). Introduction of this point mutation into HMT1 and expression of the resultant hmt1-E18V allele in PSY1191 demonstrated that cold sensitivity is mapped to this residue (Fig. 6A, lower right section).

The E18V Mutation in Hmt1p Reduces Methylation of Npl3p-- Although E18 does not lie within predicted methyltransferase motifs of Hmt1p, mutating this residue might affect methyltransferase activity of the protein. To test this possibility in vivo, the original mutant alleles and hmt1-E18V were integrated into the genome of a Delta hmt1 strain (PSY865), and lysates were immunoblotted for expression and activity of the mutant proteins (Fig. 7). The activity of all three mutant alleles, as detected by the relative abundance of methyl-Npl3p, is reduced at 14 °C compared with 25 °C, from slightly less than wild type to more than 20-fold less than wild type (Fig. 7, bottom panel). Thus cold-sensitive growth correlates with cold-sensitive methyltransferase activity.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   In vivo methylation of Npl3p by cold-sensitive Hmt1p. Cold-sensitive hmt1 alleles were integrated into the genome as in Fig. 2C. Cells were grown and lysed, and total protein was used for immunoblot analysis of the expression and activity of the mutant proteins. Lysate from Delta hmt1 strains and a 5-fold dilution series of wild-type HMT1 lysate (same as Fig. 2) are shown for comparison. Lanes 1, 2, 5-9, 12-14 contain 5 µg of total protein, lanes 3 and 10 contain 1 µg, and lanes 4 and 11 contain 0.2 µg of total protein for anti-Hmt1p and anti-methyl-Npl3p. Half as much lysate was used for anti-Npl3p blots.

Histidine-tagged E18V Hmt1p was expressed in bacteria, purified, and tested for methylation of recombinant Npl3p-myc and His-Hrp1p. Although methylation of Npl3-myc by recombinant E18V Hmt1p was equivalent to that by wild-type Hmt1p at 30 °C, [methyl-3H]Npl3-myc was significantly reduced for E18V reactions incubated at 14 °C (Fig. 8A). To test whether the cold sensitivity of methyltransferase activity was substrate-specific, methylation of His-Hrp1p, a synthetic peptide substrate, and GST-Hrb1p were tested at two temperatures (Fig. 8, B and C, and data not shown). A higher concentration of the peptide substrate was used to allow detection of the tritiated peptide within a responsive range of enzyme-to-substrate ratios. Notably, hmt1-E18V appeared to methylate these substrates as well as, if not better than, wild-type Hmt1p at both temperatures, suggesting that the hmt1-E18V defect is specific for Npl3p (Fig. 8, B and C, and data not shown).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 8.   In vitro activity of wild-type and E18V Hmt1p. A, recombinant Npl3-myc (0.7 µM) was incubated in the presence of [methyl-3H]SAM and increasing amounts of wild-type (WT, lanes 1, 3, 5) or E18V (lanes 2, 4, 6) mutant His-Hmt1p (lanes 1 and 2, 0.07 µM; lanes 3 and 4, 0.7 µM; lanes 5 and 6, 7 µM enzyme) at 14 °C or 30 °C for 30 min. Proteins were resolved by SDS-PAGE and visualized by fluorography. B, recombinant His-Hrp1p was tested for methylation by wild-type and mutant His-Hmt1 proteins exactly as described in A. C, a synthetic peptide with a single site for methylation (100 µM) was incubated in the presence of increasing amounts of wild-type (lanes 1, 3, 5) or E18V (lanes 2, 4, 6) His-Hmt1p (lanes 1 and 2, 0.1 µM; lanes 3 and 4, 1 µM; lanes 5 and 6, 10 µM enzyme). Methylation of the peptide was detected as in A.

To test whether the hmt1-E18V allele was synthetically lethal with npl3-1, a hmt1-E18V strain (PSY1686) was crossed to a npl3-1 strain (PSY773; Ref. 43). After sporulation of the diploid, 20 tetrads were dissected: 6 parental ditypes, 3 nonparental ditypes, and 11 tetratypes. Only two spores of nonparental ditypes and three spores of the tetratypes were viable, and in each case the inviable spore was predicted to be hmt1-E18V npl3-1 (Leu+, temperature-sensitive phenotype). Thus the cold-sensitive hmt1 allele was synthetically lethal with npl3-1, as expected if methylation of npl3-1p is important for strain viability.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The primary yeast protein arginine methyltransferase, Hmt1p, has been shown to be essential for viability of strains with mutations in the RNA-binding proteins Npl3p and Cbp80 (4, 9). In this report, the introduction of point mutations into the co-factor binding site of Hmt1p, one of which abolishes its enzymatic activity, has revealed that its methyltransferase activity is crucial for the survival of these strains. Random mutagenesis of HMT1 led to the identification of a cold-sensitive allele, hmt1-E18V. The N-terminal E18V substitution affected in vitro methylation of Npl3p but not of other substrates.

The cofactor-binding site of methyltransferases comprises both specific residues for SAM coordination and a loop that lies between a beta -sheet and an alpha -helix (18, 40). The methyltransferase motif I contains the loop residues, and the third amino acid in the loop, corresponding to G68 in Hmt1p, is structurally constrained (40). Given the sizes of the amino acids substituted for glycine at this residue, arginine would be expected to perturb SAM binding by Hmt1p to a greater extent than alanine would. Correspondingly, no methyltransferase activity of Hmt1-G68R was detected in vivo or in vitro, whereas the activity of Hmt1-G68A was detectable but significantly reduced. The lower activity of Hmt1-G68A protein was sufficient to partially suppress the Delta hmt1 Delta cbp80 synthetic lethality but not that of Delta hmt1 npl3-1.

Upon sequencing of the original hmt1-1 allele, which was found to be synthetically lethal with npl3-1 (4), we found a mutation that would result in a glycine-to-aspartate change at residue 86 (asterisk, Fig. 1B; data not shown). The location of this mutation in the post-I methyltransferase motif, which is also thought to be involved in SAM binding (3, 39), suggests that the lethality of the hmt1-1 npl3-1 strain may also be due to defective cofactor binding and a concomitant reduction in methyltransferase activity.

We were interested in determining whether there are any regions of Hmt1p other than those implicated in SAM binding that are important for its biological function. Such regions might, for example, be involved in Hmt1p-substrate interactions. The change of a glutamate to a valine at residue 18 of Hmt1p caused cold sensitivity of a Delta cbp80 strain; in a npl3-1 strain, the hmt1-E18V allele was lethal. The E18V substitution resulted in an enzyme with lowered methyltransferase activity toward Npl3p, but not other substrates, at low temperature. This in vitro substrate specificity and the location of residue 18 N-terminal to the defined methyltransferase motifs suggest that this residue might be involved in substrate binding or positioning rather than catalysis. It is not yet clear why a mutation that affects Npl3p methylation causes cold sensitivity in the Delta cbp80 background, but both NPL3 and CBP80 have been implicated in RNA export.

The majority of the RNA in the cell is thought to be associated with proteins throughout its lifetime. For example, cap-binding proteins Cbp80p and Cbp20p bind nascent mRNAs co-transcriptionally and are joined by splicing and polyadenylation factors (e.g. Hrp1p) and other nuclear RNA-binding proteins, such as Npl3p (44) (Fig. 9). These proteins are likely to escort the RNAs through the nucleus and nuclear pores to the cytoplasm and to be exchanged for cytoplasmic proteins before translation. In Delta hmt1 cells, in which Npl3p export is severely slowed, Cbp80 may expedite the export of mRNAs and allow survival (9). Conversely, in the absence of Cbp80, RNA export may require the efficient methylation of Npl3p, which is inhibited at low temperature in hmt1-E18V cells. Alternatively, the E18V mutation may disrupt methylation of another substrate that is required at low temperature in the absence of CBP80. Future studies should help to define the interactions among these genes implicated in RNA binding and nuclear transport.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 9.   Model: Hmt1p and nuclear transport. Proteins involved in nuclear transport that interact with Hmt1p are shown schematically. Hrp1p and Npl3p are Hmt1p substrates, and the cap-binding protein gene CBP80 interacts genetically with HMT1. These proteins are thought to play a role in packaging mRNA for export into the cytoplasm for subsequent translation (the ribosome is indicated by 60 S and 40 S subunits).


    ACKNOWLEDGEMENTS

We thank Maurice Swanson for kindly providing the 1E4 antibody. We thank Elissa Lei, Elisa Shen, and Tracy Stage-Zimmermann for critical reading of the manuscript, Heike Krebber for npl3-27 strains, and other members of the Silver and Hogle laboratories for helpful discussions.

    FOOTNOTES

* This work was supported by National Institutes of Health Postdoctoral Fellowship GM19236 (to A. E. M.), a National Science Foundation graduate fellowship (to V. H. W.), and National Institutes of Health Grant GM57476 (to P. A. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115. Tel.: 617-632-5102; Fax: 617-632-5103; E-mail: psilver@fas.harvard.edu.

2 H. Krebber, unpublished data.

    ABBREVIATIONS

The abbreviations used are: SAM, S-adenosyl-L-methionine; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; PBST, phosphate-buffered saline with 0.25% Tween; MOPS, 4-morpholinepropanesulfonic acid; 5-FOA, 5-fluoro-orotic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Paik, W. K., and Kim, S. (1968) J. Biol. Chem. 243, 2108-2114[Abstract/Free Full Text]
2. Lin, W. J., Gary, J. D., Yang, M. C., Clarke, S., and Herschman, H. R. (1996) J. Biol. Chem. 271, 15034-15044[Abstract/Free Full Text]
3. Gary, J. D., Lin, W. J., Yang, M. C., Herschman, H. R., and Clarke, S. (1996) J. Biol. Chem. 271, 12585-12594[Abstract/Free Full Text]
4. Henry, M. F., and Silver, P. A. (1996) Mol. Cell. Biol. 16, 3668-3678[Abstract]
5. Abramovich, C., Yakobson, B., Chebath, J., and Revel, M. (1997) EMBO J. 16, 260-266[CrossRef][Medline] [Order article via Infotrieve]
6. Niewmierzycka, A., and Clarke, S. (1999) J. Biol. Chem. 274, 814-824[Abstract/Free Full Text]
7. Birney, E., Kumar, S., and Krainer, A. R. (1993) Nucleic Acids Res. 21, 5803-5816[Abstract/Free Full Text]
8. Kim, S., Merrill, B. M., Rajpurohit, R., Kumar, A., Stone, K. L., Papov, V. V., Schneiders, J. M., Szer, W., Wilson, S. H., Paik, W. K., and Williams, K. R. (1997) Biochemistry 36, 5185-5192[CrossRef][Medline] [Order article via Infotrieve]
9. Shen, E. C., Henry, M. F., Weiss, V. H., Valentini, S. R., Silver, P. A., and Lee, M. S. (1998) Genes Dev. 12, 679-691[Abstract/Free Full Text]
10. Casellas, P., and Jeanteur, P. (1978) Biochim. Biophys. Acta 519, 243-254[Medline] [Order article via Infotrieve]
11. Ghosh, S. K., Paik, W. K., and Kim, S. (1988) J. Biol. Chem. 263, 19024-19033[Abstract/Free Full Text]
12. Miyake, M. (1975) J. Neurochem. 24, 909-915[CrossRef][Medline] [Order article via Infotrieve]
13. Rajpurohit, R., Paik, W. K., and Kim, S. (1992) Biochim. Biophys. Acta 1122, 183-188[CrossRef][Medline] [Order article via Infotrieve]
14. Liu, Q., and Dreyfuss, G. (1995) Mol. Cell. Biol. 15, 2800-2808[Abstract]
15. Rawal, N., Rajpurohit, R., Paik, W. K., and Kim, S. (1994) Biochem. J. 300, 483-489
16. Baldwin, G. S., and Carnegie, P. R. (1971) Science 171, 579-581[Abstract/Free Full Text]
17. Kagan, R. M., and Clarke, S. (1994) Arch. Biochem. Biophys. 310, 417-427[CrossRef][Medline] [Order article via Infotrieve]
18. Schluckebier, G., O'Gara, M., Saenger, W., and Cheng, X. (1995) J. Mol. Biol. 247, 16-20[CrossRef][Medline] [Order article via Infotrieve]
19. Scott, H. S., Antonarakis, S. E., Lalioti, M. D., Rossier, C., Silver, P. A., and Henry, M. F. (1998) Genomics 48, 330-340[CrossRef][Medline] [Order article via Infotrieve]
20. Siebel, C. W., and Guthrie, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13641-13646[Abstract/Free Full Text]
21. Lee, M. S., Henry, M., and Silver, P. A. (1996) Genes Dev. 10, 1233-1246[Abstract/Free Full Text]
22. Singleton, D. R., Chen, S., Hitomi, M., Kumagai, C., and Tartakoff, A. M. (1995) J. Cell Sci. 108, 265-272[Abstract]
23. Russell, I. D., and Tollervey, D. (1992) J. Cell Biol. 119, 737-747[Abstract/Free Full Text]
24. Bossie, M. A., DeHoratius, C., Barcelo, G., and Silver, P. (1992) Mol. Biol. Cell 3, 875-893[Abstract]
25. Loo, S., Laurenson, P., Foss, M., Dillin, A., and Rine, J. (1995) Genetics 141, 889-902[Abstract]
26. Kessler, M. M., Henry, M. F., Shen, E., Zhao, J., Gross, S., Silver, P. A., and Moore, C. L. (1997) Genes Dev. 11, 2545-2556[Abstract/Free Full Text]
27. Valentini, S. R., Weiss, V. H., and Silver, P. A. (1999) RNA (N. Y.) 5, 272-280[Abstract]
28. Frankel, A., and Clarke, S. (1999) Biochem. Biophys. Res. Commun. 259, 391-400[CrossRef][Medline] [Order article via Infotrieve]
29. Lewis, J. D., Gorlich, D., and Mattaj, I. W. (1996) Nucleic Acids Res. 24, 3332-3336[Abstract/Free Full Text]
30. Lewis, J. D., Izaurralde, E., Jarmolowski, A., McGuigan, C., and Mattaj, I. W. (1996) Genes Dev. 10, 1683-1698[Abstract/Free Full Text]
31. Lewis, J. D., and Izaurralde, E. (1997) Eur. J. Biochem. 247, 461-469[Medline] [Order article via Infotrieve]
32. Visa, N., Izaurralde, E., Ferreira, J., Daneholt, B., and Mattaj, I. W. (1996) J. Cell Biol. 133, 5-14[Abstract/Free Full Text]
33. Rose, M. D., Winston, F., and Hieter, P. (1990) Methods in Yeast Genetics: A Laboratory Course Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
34. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
35. Seedorf, M., Damelin, M., Kahana, J., Taura, T., and Silver, P. A. (1999) Mol. Cell. Biol. 19, 1547-1557[Abstract/Free Full Text]
36. Wilson, S. M., Datar, K. V., Paddy, M. R., Swedlow, J. R., and Swanson, M. S. (1994) J. Cell Biol. 127, 1173-1184[Abstract/Free Full Text]
37. Krebber, H., Taura, T., Lee, M. S., and Silver, P. A. (1999) Genes Dev. 13, 1994-2004[Abstract/Free Full Text]
38. Cadwell, R. C., and Joyce, G. F. (1992) PCR Methods Applications 2, 28-33[Medline] [Order article via Infotrieve]
39. Gary, J. D., and Clarke, S. (1998) Prog. Nucleic Acid Res. Mol. Biol. 61, 65-131[Medline] [Order article via Infotrieve]
40. Djordjevic, S., and Stock, A. M. (1997) Structure 5, 545-558[Medline] [Order article via Infotrieve]
41. Ahmad, I., and Rao, D. N. (1996) J. Mol. Biol. 259, 229-240[CrossRef][Medline] [Order article via Infotrieve]
42. Orr-Weaver, T. L., and Szostak, J. W. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 4417-4421[Abstract/Free Full Text]
43. Henry, M., Borland, C. Z., Bossie, M., and Silver, P. A. (1996) Genetics 142, 103-115[Abstract]
44. Izaurralde, E., and Adam, S. (1998) RNA (N. Y.) 4, 351-364[Abstract]
45. Christianson, T. W., Sikorski, R. S., Dante, M., Shero, J. H., and Hieter, P. (1992) Gene 110, 119-122[CrossRef][Medline] [Order article via Infotrieve]
46. Sikorski, R. S., and Hieter, P. (1989) Genetics 122, 19-27[Abstract/Free Full Text]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Eukaryot CellHome page
A. E. McBride, C. Zurita-Lopez, A. Regis, E. Blum, A. Conboy, S. Elf, and S. Clarke
Protein Arginine Methylation in Candida albicans: Role in Nuclear Transport
Eukaryot. Cell, July 1, 2007; 6(7): 1119 - 1129.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
M. C. Yu, D. W. Lamming, J. A. Eskin, D. A. Sinclair, and P. A. Silver
The role of protein arginine methylation in the formation of silent chromatin
Genes & Dev., December 1, 2006; 20(23): 3249 - 3254.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Ostareck-Lederer, D. H. Ostareck, K. P. Rucknagel, A. Schierhorn, B. Moritz, S. Huttelmaier, N. Flach, L. Handoko, and E. Wahle
Asymmetric Arginine Dimethylation of Heterogeneous Nuclear Ribonucleoprotein K by Protein-arginine Methyltransferase 1 Inhibits Its Interaction with c-Src
J. Biol. Chem., April 21, 2006; 281(16): 11115 - 11125.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. E. McBride, J. T. Cook, E. A. Stemmler, K. L. Rutledge, K. A. McGrath, and J. A. Rubens
Arginine Methylation of Yeast mRNA-binding Protein Npl3 Directly Affects Its Function, Nuclear Export, and Intranuclear Protein Interactions
J. Biol. Chem., September 2, 2005; 280(35): 30888 - 30898.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
M. C. Yu, F. Bachand, A. E. McBride, S. Komili, J. M. Casolari, and P. A. Silver
Arginine methyltransferase affects interactions and recruitment of mRNA processing and export factors
Genes & Dev., August 15, 2004; 18(16): 2024 - 2035.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.